"Obesity and thinness are two sides of the same coin, and with our partners at Merck we are working to identify the best targets for therapeutic intervention within this pathway, as well as compounds that are effective against these targets, " DeCode Chief Executive Kari Stefansson said in the statement.
DeCode (nasdaq: DCGN - news - people ) said in its statement this morning that one form of the gene predisposed people to become fat, while another predisposed them to be thin.